| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A final comment
|
Drummond, Michael F.
|
|
2002
|
3 |
2 |
p. 142
|
artikel
|
| 2 |
Association of time preference for health with age and disease severity
|
Stavem, K.
|
|
2002
|
3 |
2 |
p. 120-124
|
artikel
|
| 3 |
Burden of illness imposed by severe sepsis in Germany
|
Schmid, A.
|
|
2002
|
3 |
2 |
p. 77-82
|
artikel
|
| 4 |
Commentary
|
Jönsson, Bengt
|
|
2002
|
3 |
2 |
p. 139
|
artikel
|
| 5 |
Commentary
|
Schulenburg, J.-Matthias Graf von der
|
|
2002
|
3 |
2 |
p. 138
|
artikel
|
| 6 |
Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine
|
Radbruch, Lukas
|
|
2002
|
3 |
2 |
p. 111-119
|
artikel
|
| 7 |
Developing a scoring system to quality assess economic evaluations
|
Gonzalez-Perez, J. G.
|
|
2002
|
3 |
2 |
p. 131-136
|
artikel
|
| 8 |
Drug licensing requirements are changing!
|
Lekkerkerker, F.
|
|
2002
|
3 |
2 |
p. 141-142
|
artikel
|
| 9 |
Erratum to: Does health technology assessment benefit health services and politics?
|
Sigmund, H.
|
|
2002
|
3 |
2 |
p. 124
|
artikel
|
| 10 |
Genetic testing and the health care system
|
Schöffski, Oliver
|
|
2002
|
3 |
2 |
p. 73-76
|
artikel
|
| 11 |
Is EQ-5D a valid measure of HRQoL in patients with movement disorders?
|
Ghislandi, S.
|
|
2002
|
3 |
2 |
p. 125-130
|
artikel
|
| 12 |
Reputation, public information, and physician adoption of an innovation
|
Smythe, J. G.
|
|
2002
|
3 |
2 |
p. 103-110
|
artikel
|
| 13 |
Risk-adjusted capitation funding models for chronic disease in Australia: alternatives to casemix funding
|
Antioch, K. M.
|
|
2002
|
3 |
2 |
p. 83-93
|
artikel
|
| 14 |
The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom
|
Bonastre, J.
|
|
2002
|
3 |
2 |
p. 94-102
|
artikel
|
| 15 |
Time for a change in drug licensing requirements?
|
Drummond, Michael F.
|
|
2002
|
3 |
2 |
p. 137-138
|
artikel
|
| 16 |
Time for a change in drug pricing : Going downstream
|
Pouvourville, Gérard de
|
|
2002
|
3 |
2 |
p. 140-141
|
artikel
|
Tijdschrift beschrijving